GT Biopharma Inc reports results for the quarter ended in March - Earnings Summary

GT Biopharma

16/05/2023 24:17

* GT Biopharma Inc  GTBP.OQ  reported a quarterly adjusted
loss of
1 cent​​ per share for the quarter ended in March. The mean
expectation of two analysts for the quarter was for a loss of 14
cents per share.
    * Reported revenue was zero​; analysts expected zero. 
    * GT Biopharma Inc's reported EPS for the quarter was a loss
of 1
cent​.
    * The mean earnings estimate of analysts had risen by
about 12.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * GT Biopharma Inc shares had fallen by 48.2% this
quarter and
lost 67.8% so far this year.
    * The company reported a quarterly loss of $227 thousand.
    * Wall Street's median 12-month price target for GT
Biopharma Inc
is $3.50 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data May
15 at 11:17 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2023      -0.14          -0.01          Beat
 Dec. 31 2022      -0.17          -0.18          Missed
 Sep. 30 2022      -0.11          -0.22          Missed
 Jun. 30 2022      -0.17          -0.10          Beat